GlassScriptPhysician profile
Leon Kujmanian
NPI 1194827782
$6,864.87
in general payments reported to CMS, 2019-2025
41 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,060 · 2020: $1,306 · 2021: $994 · 2022: $446 · 2023: $781 · 2024: $643 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,736.30 | 2019-2025 | Ozempic, Rybelsus |
| Dexcom, INC. | $572.56 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $467.17 | 2019-2024 | |
| Abbott Laboratories | $456.16 | 2019-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $411.02 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $354.91 | 2019-2021 | |
| Abbvie INC. | $353.74 | 2020-2025 | |
| Lilly USA, LLC | $350.20 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $294.33 | 2019-2025 | Repatha, Repatha, Evenity |
| Mannkind Corporation | $241.05 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $207.70 | 2019-2021 | |
| Medtronic Minimed, INC. | $177.14 | 2019 | |
| Medtronic, INC. | $143.11 | 2023-2025 | Minimed 780g |
| Novartis Pharmaceuticals Corporation | $102.15 | 2021-2025 | |
| Amarin Pharma, INC. | $99.69 | 2019-2020 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Kujmanian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.